罗特西普用于较低危骨髓增生异常综合征/肿瘤患者:系统评价与Meta分析
该系统评价与Meta分析检索6个数据库至2025年3月,纳入20项研究共3455例输血依赖的较低危骨髓增生异常综合征患者,评估罗特西普的疗效与安全性。汇总8周输血独立率为51.2%,环状铁粒幼细胞阳性患者为57.8%,低输血负荷患者为72.9%;最常见不良事件为外周水肿、腹泻和疲乏。
要点
- 汇总8周输血独立率为51.2%,环状铁粒幼细胞阳性者为57.8%,低输血负荷者为72.9%。
- 12周和24周输血独立率分别为57.0%和35.8%,红系血液学改善率为51.3%。
- 严重不良事件发生率为28.0%,最常见不良事件为外周水肿、腹泻和疲乏。
核心结论
- 罗特西普是输血依赖的较低危骨髓增生异常综合征贫血的有效且耐受性良好的治疗,尤其在环状铁粒幼细胞阳性和低输血负荷患者中。
- 其良好的安全性特征和较高的输血独立率,尤其在未接受促红细胞生成素刺激剂的人群中,支持其用于一线治疗。
研究设计与样本
- 系统评价与Meta分析,检索6个数据库至2025年3月,由2名独立作者筛选和提取资料。
- 共纳入20项研究,涵盖3455例患者。
主要发现
- 汇总8周输血独立率为51.2%(95%CI 39.9-60.4;I²=94.9%)。
- 环状铁粒幼细胞阳性患者8周输血独立率为57.8%(95%CI 47.4-67.7;I²=86%)。
- 低输血负荷患者8周输血独立率为72.9%(95%CI 60.4-82.6;I²=0%)。
- 12周和24周输血独立率分别为57.0%(95%CI 48.1-65.5;I²=90%)和35.8%(95%CI 28.7-43.6;I²=82.1%)。
- 红系血液学改善率为51.3%(95%CI 41.3%-61.2%;I²=93%)。
关键数值与推荐
- 最常见不良事件:外周水肿17.8%(95%CI 11.4-26.8)、腹泻15.6%(95%CI 8.2-27.7)、疲乏11.4%(95%CI 5.4-22.6)。
- 严重不良事件发生率为28.0%(95%CI 12.8-50.7;I²=97.2%)。
临床怎么用
- 原文结论支持罗特西普用于输血依赖的较低危骨髓增生异常综合征贫血的一线治疗,尤其在环状铁粒幼细胞阳性和低输血负荷患者中。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Luspatercept has emerged as a novel therapy for anemia in transfusion-dependent (TD) lower-risk myelodysplastic syndromes (LR-MDS). This systematic review and meta-analysis aimed to evaluate the efficacy and safety of luspatercept in TD LR-MDS. Six databases were searched through March 2025 to find relevant material. Studies were screened and extracted by 2 independent authors. A total of 20 studies encompassing 3455 patients were included in the analysis. The pooled 8-week transfusion independence (TI) rate was 51.2% (95% confidence interval [CI], 39.9-60.4; I2 = 94.9%), with higher rates observed among ring sideroblast-positive (RS+) patients (57.8%; 95% CI, 47.4-67.7; I2 = 86%) and those with low transfusion burden (LTB; 72.9%; 95% CI, 60.4-82.6; I2 = 0%). The 12-week and 24-week TI rates were 57.0% (95% CI, 48.1-65.5; I2 = 90%) and 35.8% (95% CI, 28.7-43.6; I2 = 82.1%), respectively. Hematologic improvement-erythroid was achieved in 51.3% of patients (95% CI, 41.3%-61.2%; I2 = 93%). The most frequent adverse events were peripheral edema (17.8%; 95% CI, 11.4-26.8), diarrhea (15.6%; 95% CI, 8.2-27.7), and fatigue (11.4%; 95% CI, 5.4-22.6). Serious adverse events occurred in 28.0% of patients (95% CI, 12.8-50.7; I2 = 97.2%). Luspatercept is an effective and well-tolerated treatment for anemia in TD LR-MDS, especially in patients with RS+ and LTB. Its favorable safety profile and high TI rates, particularly in erythropoiesis-stimulating agent-naïve populations, support its use in the frontline setting.
引用
- Alhajahjeh A, Woite NL, Rolles B, et al. Luspatercept for patients with lower-risk myelodysplastic syndromes/neoplasms: a systematic review and meta-analysis. Blood Adv. 2025. PMID: 40966428. doi:10.1182/bloodadvances.2025017611
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。